Anzeige
Meldung des Tages: NASDAQ, Washington, Psychedelika – und Optimi steht im Zentrum der Explosion

Molecular Partners News

Aktie
WKN:  A12DEH ISIN:  CH0256379097 US-Symbol:  MLLCF Branche:  Biotechnologie Land:  Schweiz
3,535 €
-0,05 €
-1,39%
07:30:59 Uhr
Depot/Watchlist
Marktkapitalisierung *
135,87 Mio. €
Streubesitz
47,81%
KGV
-3,02
Index-Zuordnung
-

Molecular Partners News

19.04.26 - GlobeNewswire
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
MP0632 nominated as first logic-​gated Switch-​DARPin T cell engager candidate for the treatment of MSLN/EpCAM expressing solid tumors, with preclinical data indicating favorable ...
14.04.26 - GlobeNewswire
Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting
ZURICH-​SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; ...
23.03.26 - GlobeNewswire
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors
ZURICH-​SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-​stage biotech ...
19.03.26 - GlobeNewswire
Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes
Highly comparable biodistribution profiles of Radio-​DARPin candidates labeled with imaging isotopes  177 Lu or 203 Pb allows for rapid expansion of pipeline with multiple ...
17.03.26 - GlobeNewswire
Molecular Partners to Hold Three Poster Presentations at AACR 2026
ZURICH-​SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-​stage biotech ...
12.03.26 - GlobeNewswire
Molecular Partners Reports Highlights and Financial Results for Full Year 2025
Initiated US Phase 1/2a study of DLL3-targeting 212 Pb-based Radio-​DARPin candidate MP0712 for SCLC and other neuroendocrine cancers, co-​developed with strategic partner ...
26.02.26 - GlobeNewswire
Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics
Partnership with leading nuclear medicine specialist enables advancing pipeline of wholly-​owned Radio-​DARPin therapeutics for imaging and therapeutic radio-​isotopes, including ...
26.02.26 - GlobeNewswire
Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results
ZURICH-​SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-​stage biotech ...
02.02.26 - GlobeNewswire
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancers Dosimetry data highlight ...
11.01.26 - GlobeNewswire
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
Phase 1/2a study with lead Radio-​DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026 Full imaging and dosimetry data from MP0712 ...
18.12.25 - GlobeNewswire
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference
ZURICH-​SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-​stage biotech ...
11.12.25 - GlobeNewswire
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics
Chaired by globally renowned nuclear medicine expert Prof. Ken Herrmann, M.D. Other Board members James Cook, Jason Lewis, Ph.D., and Michael Morris, M.D. bring significant ...
07.12.25 - GlobeNewswire
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimens Accelerated step-up dosing and higher dosing frequency is feasible and results in ...
12.11.25 - GlobeNewswire
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action
Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-...
03.11.25 - GlobeNewswire
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting
ZURICH-​SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR  Molecular Partners AG (SIX: MOLN; ...
03.11.25 - GlobeNewswire
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025
Poster presentation outlines potential of CD3 Switch-​DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell ...
30.10.25 - GlobeNewswire
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025
IND application filed for MP0712, the Company’s lead Radio-​DARPin candidate targeting DLL3 and co-​developed with Orano Med, with Phase 1 initiation expected before year end ...
25.08.25 - GlobeNewswire
Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025
MP0533 data presented at European Hematology Association (EHA) highlights improved response rates and antitumor activity in low disease burden patients; additional data under ...
21.08.25 - GlobeNewswire
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics
Extensive experience from senior oncology research roles at Roche, MorphoSys, Boehringer Ingelheim and most recently CSO at SOTIO Biotech ZURICH-​SCHLIEREN, Switzerland ...
22.06.25 - GlobeNewswire
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025
MP0726, a Radio-​DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with ...

Newssuche

Videos

newspaper
19.04.26
CRASH-​ALARM?! Steht die nächste Baisse unmittelbar bevor?
Mehr »